Stryker (NYSE:SYK) Releases FY 2026 Earnings Guidance

Stryker (NYSE:SYK) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 14.900-15.100 for the period, compared to the consensus estimate of 14.950. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research firms have commented on SYK. Sanford C. Bernstein increased their price objective on shares of Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Leerink Partners began coverage on shares of Stryker in a report on Monday, April 13th. They set an “outperform” rating and a $410.00 price objective for the company. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a report on Tuesday, January 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $421.11.

Stryker Trading Down 0.2%

Shares of NYSE:SYK traded down $0.49 during trading on Thursday, reaching $314.64. The company’s stock had a trading volume of 2,751,278 shares, compared to its average volume of 2,059,577. The company has a current ratio of 1.89, a quick ratio of 1.21 and a debt-to-equity ratio of 0.66. Stryker has a 12 month low of $311.31 and a 12 month high of $404.87. The firm’s 50 day simple moving average is $346.83 and its two-hundred day simple moving average is $357.24. The stock has a market capitalization of $120.50 billion, a PE ratio of 37.46, a price-to-earnings-growth ratio of 1.92 and a beta of 0.92.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.00 by ($0.40). The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.36 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts predict that Stryker will post 14.91 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 41.90%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.60% of the stock is currently owned by insiders.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Reported net income and cash generation improved — operating profit and net income rose year-over-year and operating cash flow grew sharply, supporting liquidity and buyback/capex flexibility. Quiver Quant: Q1 results
• Positive Sentiment: Company maintained full-year profit outlook (FY26 EPS guidance ~14.90–15.10), which helps limit downside by giving investors visibility on management’s longer‑term plan. Reuters: misses estimates
• Neutral Sentiment: Company said it recovered from a recent cyber incident and continued serving customers, reducing operational disruption risk going forward. WSJ: cyberattack recovery
• Negative Sentiment: Q1 adjusted EPS and revenue missed consensus — adjusted EPS reported at $2.60 (below ~$3.00 consensus) and revenue $6.02B vs. estimates near $6.3–6.4B — the headline EPS/revenue miss is the main driver of the stock move. Zacks: EPS & revenue lag
• Negative Sentiment: Adjusted operating margin contracted (~180 bps) and adjusted EPS fell year-over-year, signaling margin pressure despite reported profit growth. GlobeNewswire: operating results
• Negative Sentiment: Demand softness for implants and devices used in complex spinal/orthopedic procedures weighed on revenue — a product/volume weakness story that could concern growth expectations if it persists. Reuters: muted demand
• Negative Sentiment: Significant insider and institutional selling noted in recent filings (large block sales and portfolio reductions), which can add downward pressure on the stock’s sentiment. Quiver Quant: insider & institutional activity

Institutional Trading of Stryker

Institutional investors have recently added to or reduced their stakes in the company. United Financial Planning Group LLC bought a new stake in Stryker in the third quarter worth about $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker in the fourth quarter worth about $27,000. Strive Asset Management LLC bought a new stake in Stryker in the third quarter worth about $30,000. Birchwood Financial Partners Inc. bought a new stake in Stryker in the fourth quarter worth about $35,000. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Stryker during the fourth quarter worth approximately $49,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.